Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2545studies indexed1158with human data159registered trials2232carry a numeric findingLibrarian added 0 studies today
Showing 10 studiesSortNewest indexed ▾
B
grade
Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study.
Triptorelin · Urologic oncology · 2026 · Observational · n=6666
LHRH agonists appear to be associated with a lower risk of major cardiovascular events compared to LHRH antagonists in patients with metastatic hormone-sensitive prostate cancer, but further research is needed to validate these results.
HR for MACE with LHRH-AG vs LHRH-AN was 0.86, 95% CI: 0.79-0.93.
B
grade
Optimizing ovarian stimulation in oocyte donation: exploratory comparison of rhFSH (2:1) versus hp-hMG under PPOS protocols.
Triptorelin · JBRA assisted reproduction · 2023 · Observational · n=36
In this exploratory study, rhFSH:rhLH resulted in a higher mean number of good-morphology blastocysts compared to hp-hMG, but further research is necessary to validate these findings.
Mean number of good-morphology blastocysts per cycle was 4.5 with rhFSH:rhLH vs 2.0 with hp-hMG.
B
grade
Treatment Outcomes in 84 Male Children with Accelerated Pubertal Progression: A Comparative Analysis ofGnRHa, Combined GH Therapy and Aromatase Inhibitor
Triptorelin · biorxiv-preprint · 2026 · Observational
Combination therapy with GnRHa and growth hormone shows the most promise for improving predicted adult height in boys with accelerated pubertal progression. Aromatase inhibitors may serve as a viable alternative for certain patients.
ΔH/y of combination therapy was 8.49 ± 3.22 cm/y, GnRHa was 6.73 ± 1.95 cm/y, and AI was 7.75 ± 1.92 cm/y, P < 0.01.
B
grade
Perceived Stress During Gender-Affirming Hormone Therapy: A Comparative Study of Feminizing and Masculinizing Hormone Therapy in an International Multicenter Prospective Cohort
Triptorelin · biorxiv-preprint · 2025 · Observational
This study found no significant changes in perceived stress levels after 3 or 12 months of gender-affirming hormone therapy, indicating that improvements in well-being may not reduce stress.
No significant changes in perceived stress were observed after 3 months (-1.0, p = 0.21).
Showing 10 of 10